- Home
- EVV vs CVAC Comparison
EVV vs CVAC Comparison
Compare EVV & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- CVAC
- Stock Information
- Founded
- EVV 2003
- CVAC 2000
- Country
- EVV United States
- CVAC Germany
- Employees
- EVV N/A
- CVAC N/A
- Industry
- EVV Finance/Investors Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- CVAC Health Care
- Exchange
- EVV Nasdaq
- CVAC Nasdaq
- Market Cap
- EVV 1.2B
- CVAC 1.2B
- IPO Year
- EVV N/A
- CVAC 2020
- Fundamental
- Price
- EVV $10.04
- CVAC $5.41
- Analyst Decision
- EVV
- CVAC Hold
- Analyst Count
- EVV 0
- CVAC 3
- Target Price
- EVV N/A
- CVAC $6.83
- AVG Volume (30 Days)
- EVV 323.7K
- CVAC 864.1K
- Earning Date
- EVV 01-01-0001
- CVAC 08-14-2025
- Dividend Yield
- EVV 9.66%
- CVAC N/A
- EPS Growth
- EVV N/A
- CVAC N/A
- EPS
- EVV N/A
- CVAC 0.87
- Revenue
- EVV N/A
- CVAC $566,039,775.00
- Revenue This Year
- EVV N/A
- CVAC N/A
- Revenue Next Year
- EVV N/A
- CVAC $24.04
- P/E Ratio
- EVV N/A
- CVAC $6.24
- Revenue Growth
- EVV N/A
- CVAC 787.60
- 52 Week Low
- EVV $8.52
- CVAC $2.37
- 52 Week High
- EVV $10.07
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- EVV 41.74
- CVAC 56.80
- Support Level
- EVV $10.03
- CVAC $5.35
- Resistance Level
- EVV $10.14
- CVAC $5.48
- Average True Range (ATR)
- EVV 0.06
- CVAC 0.06
- MACD
- EVV -0.02
- CVAC -0.04
- Stochastic Oscillator
- EVV 6.38
- CVAC 42.86
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.